Who
Lonnel Coats
Director
Company insider
Files Form 4 as: Director, Mineralys Therapeutics; Director, Relay Therapeutics; Director, Verve Therapeutics; Director, Blueprint Medicines; Chief Executive Officer, Lexicon Pharmaceuticals.
In numbers
- Trades disclosed
- 183
- Buys
- 12
- Sells
- 3
- Bought
- $1.1M
- Sold
- $2.7M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 7 Jul 2014
- Last trade
- 19 Oct 2026
- Last filed
- 20 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 20 Oct 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,400 at $0.00 | filing |
| 19 Oct 2026filed 20 Oct 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,600 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,947 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,947 at $0.00 | filing |
| 4 Nov 2025filed 6 Nov 2025 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —207,931 at $0.00 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code D | —136,139 | filing |
| 25 Jul 2025filed 28 Jul 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code D | —42,200 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —11,818 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —10,909 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —10,909 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —4,875 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —3,188 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —4,500 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —5,300 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —5,300 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —4,570 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicines | SEC FORM 4 Code D | —6,144 | filing |
| 18 Jun 2025filed 24 Jun 2025 | Blueprint Medicines | SEC FORM 4 Code A | $50.0M3,902 at $12,812.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | Verve Therapeuticsoption or derivative | SEC FORM 4 Code A | —42,200 at $0.00 | filing |
| 21 Nov 2024filed 22 Nov 2024 | Blueprint Medicines | SEC FORM 4 Sold | $932K9,824 at $94.87 | filing |
News
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coatsmanilatimes.net · 19 Oct 2026Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic CardiomyopathyLXRX · manilatimes.net · 23 Oct 2026Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular DiseaseLXRX · manilatimes.net · 21 Oct 2026
1 headline in the last 90 days name Lonnel Coats; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.